Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? (DEFICIT) EQUITY (UNAUDITED)

v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY (UNAUDITED) - USD ($)
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   3,654,119    
Beginning balance at Dec. 31, 2022 $ (3,008,054) $ 3,654 $ 63,726,057 $ (66,737,765)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 131,579   131,579  
Exercise of pre-funded warrants (in shares)   66,566    
Exercise of pre-funded warrants 282,905 $ 66 282,839  
Conversion of multi-draw credit agreement - related party and accrued interest (in shares)   165,517    
Conversion of multi-draw credit agreement - related party and accrued interest 2,980,521 $ 166 2,980,355  
Net loss (5,167,520)     (5,167,520)
Ending balance (in shares) at Mar. 31, 2023   3,886,202    
Ending balance at Mar. 31, 2023 (4,780,569) $ 3,886 67,120,830 (71,905,285)
Beginning balance (in shares) at Dec. 31, 2022   3,654,119    
Beginning balance at Dec. 31, 2022 (3,008,054) $ 3,654 63,726,057 (66,737,765)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss (8,279,020)      
Ending balance (in shares) at Jun. 30, 2023   3,886,202    
Ending balance at Jun. 30, 2023 (7,789,198) $ 3,886 67,223,701 (75,016,785)
Beginning balance (in shares) at Mar. 31, 2023   3,886,202    
Beginning balance at Mar. 31, 2023 (4,780,569) $ 3,886 67,120,830 (71,905,285)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 102,871   102,871  
Net loss (3,111,500)     (3,111,500)
Ending balance (in shares) at Jun. 30, 2023   3,886,202    
Ending balance at Jun. 30, 2023 (7,789,198) $ 3,886 67,223,701 (75,016,785)
Beginning balance (in shares) at Dec. 31, 2023   12,349,243    
Beginning balance at Dec. 31, 2023 (2,131,818) $ 12,349 102,238,382 (104,382,549)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 2,478,179   2,478,179  
Issuance of common stock and warrants, net of issuance costs (in shares)   15,713,664    
Issuance of common stock and warrants, net of issuance costs of $6,434,447 83,556,563 $ 15,714 83,540,849  
Net loss (5,019,531)     (5,019,531)
Ending balance (in shares) at Mar. 31, 2024   28,062,907    
Ending balance at Mar. 31, 2024 78,883,393 $ 28,063 188,257,410 (109,402,080)
Beginning balance (in shares) at Dec. 31, 2023   12,349,243    
Beginning balance at Dec. 31, 2023 (2,131,818) $ 12,349 102,238,382 (104,382,549)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss (12,922,347)      
Ending balance (in shares) at Jun. 30, 2024   28,067,907    
Ending balance at Jun. 30, 2024 72,809,051 $ 28,068 190,085,879 (117,304,896)
Beginning balance (in shares) at Mar. 31, 2024   28,062,907    
Beginning balance at Mar. 31, 2024 78,883,393 $ 28,063 188,257,410 (109,402,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense (in shares)   5,000    
Stock-based compensation expense 1,828,474 $ 5 1,828,469  
Net loss (7,902,816)     (7,902,816)
Ending balance (in shares) at Jun. 30, 2024   28,067,907    
Ending balance at Jun. 30, 2024 $ 72,809,051 $ 28,068 $ 190,085,879 $ (117,304,896)